In contrast, there was only a trend of reduced numbers of CD4+ T cells around week 12 post SCT, but overall numbers of CD3+ T cells did not significantly differ in GVHD patients compared to patients without GVHD following allo-SCT (Figure S3 in Supplementary Material). The gene discussed is CD4; the disease is graft versus host disease.